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TO THE EDITOR
Despite increasing access to antiretro-
viral drugs, sexual transmission of HIV-1
remains a significant public health
threat. A recent clinical trial, CAPRISA
004, of a vaginally administered micro-
bicide using a nucleoside reverse tran-
scriptase inhibitor (NRTI), tenofovir
(TDF), has demonstrated that 1% TDF
gel reduced HIV-1 acquisition by an
estimated 39% overall (Abdool Karim
et al., 2010), indicating a potential
utility of NRTI-based microbicides. In
the VOICE study, however, a once-daily
dosing regimen with TDF gel failed to
demonstrate protective effects in at-risk
women. These studies demonstrate the
need to develop additional more potent
microbicide candidates to potentially
increase the activity to protect women
from HIV-1 transmission.
We previously reported that a series
of 40-substituted NRTIs have excellent
antiviral properties (Ohrui, 2006), and
through optimization of such 40-
substituted NRTIs, 40-ethynyl-2-fluoro-
20-deoxyadenosine (EFdA) was found to
exert extremely potent activity against a
wide spectrum of HIV-1 strains inclu-
ding highly multidrug-resistant clinical
HIV-1 isolates, with favorable in vitro
cell toxicities (Nakata et al., 2007; Ohrui
et al., 2007). EFdA inhibited HIV-1 repli-
cation in activated peripheral blood
mononuclear cells with an EC50 of
0.05 nM, a potency several orders of mag-
nitude greater than any of the current
clinically available NRTIs (Michailidis
et al., 2009). As the prevalence of new
infections with drug-resistant HIV-1
variants could increase in the coming
years (Nichols et al., 2011), EFdA may be
useful as a topical microbicide.
Langerhans cells (LCs) are dendritic
cells located, among other sites, within
genital skin and mucosal epithelium
(Lederman et al., 2006). In female
rhesus macaques exposed intravaginally
to simian immunodeficiency virus, up to
90% of initially infected target cells were
LCs (Hu et al., 2000). Ex vivo ex-
periments with human foreskin explants
show that epidermal LCs in inner fore-
skin are primary target cells for HIV-1
infection, providing a plausible explana-
tion for why circumcision greatly reduces
the probability of acquiring HIV-1
(Ganor et al., 2010; Zhou et al., 2011).
LCs also express CD4 and CCR5, but not
CXCR4, and demonstrate the distinctive
characteristics of emigrating from tissue
to draining lymph nodes in order to
interact with T cells following contact
with pathogens (Lederman et al., 2006).
Indeed, epidermal LCs are readily
infected ex vivo with R5-HIV-1, but not
with X4-HIV-1, and initiate and promote
high levels of infection upon interactions
with cocultured CD4þ T cells
(Kawamura et al., 2000; Ogawa et al.,
2009, 2013), consistent with previous
epidemiologic observations that the
majority of HIV-1 strains isolated from
newly infected patients are R5-HIV-1
strains (Zhu et al., 1993). Thus, LCs
likely have an important role in
disseminating HIV-1 soon after
exposure to the virus.
To understand how HIV-1 traverses
skin and genital mucosa, an ex vivo
model was developed in which resident
LCs within epithelial tissue explants
obtained from suction blisters are
exposed to HIV-1 and then allowed to
emigrate from the tissue, thus mimicking
conditions that occur following mucosal
exposure to HIV (Kawamura et al.,
2000; Ogawa et al., 2009, 2013). In
this model, although relatively few pro-
ductively infected LCs are identified,
these cells induce high levels of HIV-1
infection when cocultured with resting
autologous CD4þ T cells (Kawamura
et al., 2000; Ogawa et al., 2013). As ex-
pected, when epidermal tissue explants
were pretreated with various concentra-
tions of TDF, EFdA, and CCR5 inhibitor,
maraviroc (MVC), prior to R5-tropic
HIV-1Ba-L exposure, HIV-1 infection of
resident LCs within epidermis as well as
subsequent virus transmission from
emigrated LCs to cocultured CD4þ T
cells was decreased in a dose-depen-
dent manner (Figure 1a and c; for
detailed methods, see Supplementary
Material). The blocking was confirmed
by repeated experiments using skin ex-
plants from three additional randomly
selected individuals (Figure 1b and d).
Strikingly, although the blocking
efficiency of TDF or MVC even at
5,000 nM was partial, EFdA demon-
strated complete blocking of R5-HIV-1
replication in LCs as well as subsequent
virus transmission from emigrated LCs
to CD4þ T cells at doses of 100–
5,000 nM (Figure 1a–d). Furthermore,
EFdA blocked ex vivo virus infection of
LCs as well as subsequent virus trans-
mission when two strains of R5-HIV-1,
HIV-1JR-FL and HIV-1AD8, were utilized
in experiments (n¼ 3, Supplementary
Figure S1 online).
Similar to the results in epidermal
LCs, preincubation of monocyte-derived
LCs (mLCs) with 100–5,000 nM of EFdA
completely blocked HIV-1 replication
in mLCs as well as subsequent virus
transmission from mLCs to cocultured
CD4þ T cells, whereas both TDF and
MVC at the same doses only partially
inhibited the transmission (Figure 2a
and b; for detailed methods, see
Supplementary Material online).Accepted article preview online 11 November 2013; published online 2 January 2014
Abbreviations: EFdA, 40-ethynyl-2-fluoro-20-deoxyadenosine; LC, Langerhans cell; mLC, monocyte-derived
LC; MVC, maraviroc; NRTI, nucleoside reverse transcriptase inhibitor; TDF, tenofovir
T Matsuzawa et al.
EFdA Protects LCs from HIV Infection
1158 Journal of Investigative Dermatology (2014), Volume 134
Intriguingly, even in 1–3 days follow-
ing the removal of EFdA (1,000 nM),
EFdA completely blocked HIV-1 infec-
tion of mLCs as well as subsequent
virus transmission from mLCs to cocul-
tured CD4þ T cells, whereas TDF and
MVC rapidly lost their anti-HIV-1
activity within days (Figure 2c–f). No
cellular toxicity was noted for any of
these drugs at the doses used in these
experiments (Supplementary Figure S2
online). When similar experiments
were conducted using peripheral
blood mononuclear cell as target cells,
virtually identical favorable persis-
tency of EFdA in antiviral activity
compared with that of TDF was
observed (data not shown).
In the present work, we demon-
strated that EFdA exerted extremely
more potent anti-HIV-1 activity in
LCs than did TDF and MVC, and the
potent anti-HIV-1 activity of EFdA
persisted for at least 3 days. Of note,
the efficacy of TDF gel in CAPRISA
004 has been linked to its long
intracellular half-life (Abdool Karim
et al., 2010; Rohan et al., 2010).
Our data strongly indicate that EFdA
may serve as a promising micro-
bicide to block sexual transmission of
HIV-1 because of its potent anti-HIV-1
activity, low cytotoxicity, and superior
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Figure 1. Preincubation of skin explants with EFdA blocks R5-HIV-1 infection in LCs and subsequent virus transmission to cocultured CD4þ T cells. LCs within
skin explants were preincubated with no drug (J) or the indicated concentrations of EFdA (K), TDF (m), and MVC (’) for 30 minutes, exposed to HIV-1Ba-L for
2 hours, and then floated on culture medium to allow migration of LCs from the explants. Emigrating cells from the epidermal sheets were collected 3 days
following HIV-1 exposure. HIV-1-infected LCs were assessed by HIV-1 p24 intracellular staining in langerinþ CD11cþ LCs (a, b), or further cocultured with
autologous CD4þ T cells and culture supernatants were assessed for p24 content by ELISA on the indicated days (c, d). Summary of percent inhibition of LC
infection (b) and virus transmission to CD4þ T cells (d) of 12 experiments using skin explants from 12 individuals with the indicated each concentration of
EFdA (K), TDF (m), and MVC (’) are shown. Mean values obtained from different donors are shown as horizontal marks (b, d). EFdA, 40-ethynyl-2-fluoro-20-
deoxyadenosine; LCs, Langerhans cells; MVC, maraviroc; TDF, tenofovir.
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persistence of antiviral activity against
HIV-1 in LCs.
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Figure 2. Preincubation of skin explants with EFdA blocks subsequent R5-HIV-1 infection in LC in a dose-dependent manner. mLCs were preincubated
with no drug (J) or the indicated concentrations of EFdA (K), TDF (m) and MVC (’) for 30 minutes, and then immediately exposed to HIV-1Ba-L for 2 hours
(a, b), or thoroughly washed to remove the extracellular drug and further cultured for 1, 2, or 3 days prior to exposure to HIV-1Ba-L for 2 hours (c–f). After 7 days
of HIV-1 exposure, HIV-1-infected mLCs were assessed by HIV-1 p24 intracellular staining in langerinþ CD11cþ mLCs (a, c, e), or further cocultured with
autologous CD4þ T cells and culture supernatants were assessed for p24 content by ELISA on the indicated days (b, d, f). Summary of percent inhibition of mLC
infection (a, e) and virus transmission to CD4þ T cells (b, f) of three independent experiments are shown. Mean values are shown as horizontal marks (a, b, e, f).
EFdA, 40-ethynyl-2-fluoro-20-deoxyadenosine; LCs, Langerhans cells; mLCs, monocyte-derived LCs; MVC, maraviroc; TDF, tenofovir.
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Suppression of miR135b Increases the Proliferative
Potential of Normal Human Keratinocytes
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TO THE EDITOR
Cell fate is regulated by the activation
and repression of specific genes
(Sonkoly et al., 2007), and microRNAs
(miRNAs) are a class of posttranslational
regulators of gene expression.
Psoriasis is a hyperproliferative skin
disorder (Schneider, 2012) and it has
been reported that the stratified epider-
mis expresses miR135b (Joyce et al.,
2011), which suggests that miR135b is
closely related to epidermal keratini-
zation. Previously, we isolated three
populations of epidermal cells that
differed according to their ability to
adhere to type IV collagen (Kim et al.,
2004). Rapidly adhering (RA) cells, which
are considered to be epidermal stem
cells, express high levels of a6 integrin
and low levels of CD71. In contrast,
slowly adhering (SA) cells express low
levels of a6 integrin and high levels of
CD71 (Kim et al., 2004). Type IV
collagen-coated dishes were prepared
(CellmatrixType IV, Nitta Gelatin,
Osaka, Japan) and a subpopulation of
cells able to adhere within 10 minutes at
37 1C was selected (RA cells). Thereafter,
non-adherent cells were incubated for
another 24 hours, and, among them,
slowly adhering cells were selected (SA
cells). Total RNAs were prepared
and real-time reverse-transcriptase–PCR
(RT–PCR) analysis was performed.
Levels of miR135b were significantly
higher in SA cells (three different cell
lines from three volunteers, Supplemen-
tary Figure S1 online). To test the effects
of miR135b, cultured keratinocytes were
transfected with miR135b mimic (30 nM,
AM17100, PM13044, Ambion, Austin,
TX) or mock (as negative controls,
30 nM, AM17110, Ambion). Results
showed that miR135b mimic trans-
fected cells showed abnormal changes
compared with mock-transfected cells
(Supplementary Figure S2 online). These
findings suggested that miR135b initially
induced early differentiation of keratino-
cytes. Therefore, we suppressed miR135b
to clarify whether inhibition of miR135b
might target and delay differentiation
of keratinocytes. The transfection was
performed with an anti-miRNA inhibitor
(ib-miR135b, AM17000, AM13044,
Ambion) designed for hsa-miR135b or a
negative control (AM17010, Ambion) at
a final concentration of 30 nM according
to the manufacturer’s instruction. To
check transfection efficiency, an FAM-
labeled miRNA was transfected and the
results showed successful transfection
(Supplementary Figure S3 online). There-
after, the transfected FAM-labeled
miRNA was not observed at day 7 after
transfection (Supplementary Figure S3
online), which means that the transfected
miRNA persisted only for a few days. At
every passage, transfection was repeat-
edly performed, and portions of cells
were collected for cell counting, RNA
extraction, and protein extraction. RT–
PCR analysis showed that transfection of
ib-miR135b effectively suppresses
miR135b (Figure 1a). Cumulative cell
numbers showed a large difference
(Figure 1b). A colony assay showed that
ib-miR135b-transfected cells showed a
higher colony-forming ability than
mock-transfected cells (Supplementary
Figure S4 online). At the 9th passage,
ib-miR135b-transfected cells reached
B51010 cells (Figure 1b). However,
mock-transfected cells increased to only
1.61010 cells (Figure 1b). In addition,
mock-transfected cells showed large
vacuoles earlier than ib-miR135b-trans-
fected cells (Figure 1b, arrow). Large
vacuoles frequently appeared in the
cytoplasm, especially in late passages,
during the culture of keratinocytes (per-
sonal observation). However, these find-
ings are not described in detail in the
literature. The vacuolar alteration hasAccepted article preview online 15 October 2013; published online 14 November 2013
Abbreviations: miRNA, microRNA; RA, rapidly adhering; SA, slowly adhering
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